1. Causes of hOCT1‐Dependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumor‐Selective Gene Therapy
   Elisa Lozano et al, 2019, Hepatology CrossRef
2. Treatment with decitabine induces the expression of stemness markers, PD-L1 and NY-ESO-1 in colorectal cancer: potential for combined chemoimmunotherapy
   Nassiba Taib et al, 2023, Journal of Translational Medicine CrossRef
3. DNA methylation inhibitor, decitabine, promotes MGC803 gastric cancer cell migration and invasion via the upregulation of NEDD4-1
   DONG LI et al, 2015, Molecular Medicine Reports CrossRef
4. SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma
   Maite Merino-Azpitarte et al, 2017, Journal of Hepatology CrossRef
5. Therapeutic Potential of Autophagy Modulation in Cholangiocarcinoma
   Hector Perez-Montoyo, 2020, Cells CrossRef
6. Cytotoxic activities and effects of atractylodin and β-eudesmol on the cell cycle arrest and apoptosis on cholangiocarcinoma cell line
   Kanawut Kotawong et al, 2018, Journal of Pharmacological Sciences CrossRef
7. Involvement of Epigenomic Factors in Bile Duct Cancer
   Magdalena Rogalska-Taranta et al, 2022, Seminars in Liver Disease CrossRef
8. Postsurgical wound management and prevention of triple-negative breast cancer recurrence with a pryoptosis-inducing, photopolymerizable hydrogel
   Dandan Mi et al, 2023, Journal of Controlled Release CrossRef
9. Decitabine augments cytotoxicity of cisplatin and doxorubicin to bladder cancer cells by activating hippo pathway through RASSF1A
   Madhuram Khandelwal et al, 2018, Molecular and Cellular Biochemistry CrossRef
10. Novel biomarkers for cholangiocarcinoma: how can it enhance diagnosis, prognostication, and investigational drugs? Part-1
    Ranu S Sinniah et al, 2021, Expert Opinion on Investigational Drugs CrossRef
11. Omics-Based Platforms: Current Status and Potential Use for Cholangiocarcinoma
    Yu-Chan Chang et al, 2020, Biomolecules CrossRef